Tonix Pharma Gets IND Clearance For TNX-201 In Episodic Tension-Type Headache

(RTTNews) - Tonix Pharmaceuticals Holding Corp. (TNXP) said the U.S. Food and Drug Administration has cleared its Investigational New Drug application to study TNX-201 for the treatment of episodic tension-type headache.

Tonix will evaluate the safety, tolerability, and pharmacokinetics of TNX-201 in a healthy volunteers study to be completed before the end of 2014.

"We are developing TNX-201 with the goal of providing a new prescription medication for the millions of U.S. adults who suffer from episodic tension-type headache. For many, the existing treatment options are not adequately effective," said Seth Lederman, chairman and chief executive officer of Tonix.

All of the approved prescription drugs contain the barbiturate butalbital. Barbiturates are known to impair alertness, and carry risk of dependence and addiction.